Clinical trials: Covid19 Vaccine
Chronic Lymphocytic Leukemia, COVID-19
Passive Antibodies Against COVID-19 With EVUSHELD in Vaccine Non-responsive CLL
Chronic lymphocytic leukaemia (CLL) is a common lymphoid malignancy affecting older adults. CLL patients are immunocompromised by the disease itself and by several of its therapies.
- Trial name
- PACE-CLL (NCT05465876)
- Testing
- EVUSHELD
- Where
- Canada
- Sponsor
- Sunnybrook Health Sciences Centre
COVID-19 Vaccine, COVID-19
Evaluation of Safety, Tolerability, Reactogenicity, Immunogenicity of Baiya SARS-CoV-2 Vax 2 as a Booster for COVID-19
The investigational product Baiya SARS-CoV-2 Vax 2 vaccine is a second-generation of protein subunit vaccine from plant to prevent COVID-19 disease.
- Trial name
- NCT05873374
- Testing
- 50 μg Baiya SARS-CoV-2 Vax 2
- Where
- Thailand
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Baiya Phytopharm Co., Ltd.
Comorbidities and Coexisting Conditions, Healthy
Immune Response of an Interchangeable Booster Vaccine Against COVID-19 Among Individuals With Risk Factors for Severity
Experimental, single-arm study in participants with comorbidities, previously immunized with 2 doses of CoronaVac, who will receive a booster vaccine with 1 dose of the Oxford/AstraZeneca vaccine.
- Trial name
- COVACManaus2 (NCT05289206)
- Testing
- Vaccine - ChAdOx1-S/nCoV-19 [recombinant]
- Where
- Brazil
- Volunteers
- 4,446 people, healthy volunteers welcome
- Sponsor
- Fundação de Medicina Tropical Dr. Heitor Vieira Dourado
Covid19, SARS-CoV Infection
Immunogenicity, Efficacy and Safety of QazCovid-in® COVID-19 Vaccine
Multicenter, randomized, blind, placebo-controlled clinical study of III phases on the assessment of preventive efficiency, safety and immunogenicity QazCovid-in®-vaccine against COVID-19 in healthy adult volunteers
- Conditions
- Covid19, SARS-CoV Infection, Vaccine Adverse Reaction
- Trial name
- NCT04691908
- Testing
- QazCovid-in®-vaccine against COVID-19
- Where
- Kazakhstan
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Research Institute for Biological Safety Problems
COVID-19 Immunization, Influenza Immunization
Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older
Study VBT00001 is planned to be a Phase 1/2, randomized, modified double-blind, active-controlled, multi-center study to be conducted in approximately 980 adults aged 50 years and older in the United States.
- Trial name
- NCT06695117
- Testing
- IIV-HD, rC19 (dose 1), IIV-HD + rC19 (dose 1)
- Where
- 12 sites in United States
- Volunteers
- 980 people, healthy volunteers welcome
- Sponsor
- Sanofi
COVID-19
Evaluation of COVID-19 Vaccines Given as a Booster in Healthy Adults in Indonesia (MIACoV Indonesia)
This is a randomised controlled clinical trial to determine the reactogenicity and immunogenicity of booster doses of SARS-CoV-2 vaccines (Pfizer-BioNTech, AstraZeneca or Moderna) in adults who have previously received either…
- Trial name
- NCT05387317
- Testing
- Pfizer-BioNTech Standard dose, AstraZeneca Standard dose, Pfizer-BioNTech Fractional dose
- Where
- 3 sites in Indonesia
- Volunteers
- healthy volunteers welcome
- Sponsor
- Murdoch Childrens Research Institute
SARS-CoV-2
Safety and Immunogenicity Study of GX-19N, a COVID-19 Preventive DNA Vaccine in Healthy Adults
The objective of our study is to evaluate safety, tolerability, and immunogenicity of COVID-19 preventive DNA vaccine in healthy volunteers.
- Trial name
- NCT04715997
- Testing
- GX-19N
- Where
- 5 sites in South Korea
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- Genexine, Inc.
COVID-19, Vaccine Reaction
The Immunogenicity and Safety Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Vaccine LYB001
The goal of this clinical trial is to assess the immunogenicity and safety following a heterologous booster dose of recombinant SARS-CoV-2 vaccine (CHO cell) LYB001 in adults 18-59 years of age completed two- or three-dose…
- Trial name
- NCT05928455
- Testing
- LYB001, CoronaVac
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Guangzhou Patronus Biotech Co., Ltd.
COVID-19
Covid 19 Vaccine Acceptance in Egyptian Pregnant Women
To determine vaccine acceptance and hesitancy attitudes toward coronavirus disease 2019 (COVID-19) vaccines in Egyptian pregnant women.
- Trial name
- NCT05258760
- Volunteers
- 1,100 people
- Sponsor
- Cairo University
Healthy People
Safety of UFRJvac, Trivalent COVID-19 Vaccine
Phase I study to evaluate the safety and immunogenicity of the vaccine booster with the trivalent UFRJvac COVID-19 vaccine.
- Trial name
- UFRJvac-1 (NCT06303635)
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- Azidus Brasil
Healthy
Follow-up Study of Population Vaccinated With COVID-19 Vaccine
A multi-centered clinical follow-up study to investigate the long-term dynamic of COVID-19 antibody level after vaccination.
- Trial name
- NCT04972591
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Qin Ning
COVID-19 Vaccine, Breastmilk
Is COVID-19 Transmitted Through Human Milk? Implications for Breastfeeding and Human Milk Banking-Study 1c
This will be a prospective observational study of lactating mothers who are planning to, have scheduled or have received vaccination against SARS-COV-2 (COVID-19 vaccine).
- Trial name
- NCT05004740
- Testing
- Vaccinated Pregnant or Lactating persons
- Where
- Canada
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Deborah O'Connor
Heart Transplantation, COVID-19 Virus Infection
Covid-19 Vaccine Response in Heart Transplant Recipients
Clinical studies indicate a decrease in vaccine efficacy in certain immunocompromised populations (kidney transplant recipients, patients undergoing chemotherapy).
- Conditions
- Heart Transplantation, COVID-19 Virus Infection, COVID-19 Vaccine
- Trial name
- COVHEART (NCT05268679)
- Testing
- Biospecimen Collection, Questionnaire, Electronic Health Record Review
- Where
- France
- Volunteers
- 190 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Sickle Cell Disease, COVID-19 Vaccine
COVID-19 Vaccination Hesitancy in Adults With Sickle Cell Disease
The goal of this clinical trial is to test an COVID-19 vaccination information video in adults with sickle cell disease. The main questions it aims to answer are why are some adults with sickle cell disease hesitant to receive…
- Conditions
- Sickle Cell Disease, COVID-19 Vaccine, Vaccine Hesitancy
- Trial name
- NCT05998824
- Testing
- SCD-specific COVID-19 vaccination information (SCVI) video
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Duke University
Influenza, COVID-19
Text4Vax: Text Message Reminders for Pediatric COVID-19 and Influenza Vaccines 2024-25 Season
This multi-site study assesses the impact of text message reminders on the receipt of COVID-19 and influenza text message reminders takes place primarily in practices from the American Academy of Pediatrics (AAP) Pediatric…
- Conditions
- Influenza, COVID-19, Vaccination Hesitancy
- Trial name
- NCT06603090
- Testing
- Text message influenza vaccine reminders, Text message COVID-19 vaccine reminders, Text message influenza and COVID-19 vaccine reminders
- Where
- 4 sites in United States
- Volunteers
- 66,147 people
- Sponsor
- Columbia University
COVID-19
A Clinical Observational Study of SARS-CoV-2 Specific CD8 T-Cell Responses to COVID-19 Vaccines in Humans
Background: The immune response is how the body recognizes and defends itself against foreign and harmful substances. Researchers want to compare the immune responses between young and older healthy adults after they receive…
- Trial name
- NCT04852289
- Where
- 2 sites in United States
- Volunteers
- 78 people
- Sponsor
- National Institute on Aging (NIA)
COVID-19, Coronavirus Infections
Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901a
VBI-2901a is an investigational vaccine candidate that uses enveloped virus-like particles (eVLPs) to express the spike proteins of three coronaviruses: SARS-CoV-2 (the virus that causes COVID-19 disease), SARS-CoV-1 and…
- Trial name
- NCT05548439
- Testing
- VBI-2901a
- Where
- 7 sites in Canada
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- VBI Vaccines Inc.
SARS-CoV-2
The Use of Peripheral Blood Specimens From Patients Suspected of Having SARS-CoV-2 Infections in Research Studies Intended to Support the Development of COVID-19 Detection Methods, Treatments, and/or Vaccines
Invivoscribe, Inc. and its wholly owned subsidiary LabPMM, LLC are collecting peripheral blood specimens from patients with suspected SARS-CoV-2 viral infections.
- Trial name
- NCT04391400
- Testing
- nasal pharyngeal (NP) swab samples, peripheral blood draw
- Volunteers
- 500 people
- Sponsor
- Invivoscribe, Inc.
Long COVID, COVID-19 Pandemic
Long COVID and Its Associations With Health Outcomes in Older Adults
The Peking University Health Cohort in Anning, Yunnan (PKUHC-AN) is a prospective cohort study carried out in Anning, Yunnan. The primary aim of this study is to investigate the impact of COVID-19 on older adults' health, and to…
- Conditions
- Long COVID, COVID-19 Pandemic, Elderly Infection, Vaccine Reaction
- Trial name
- NCT05825651
- Testing
- no interventions
- Where
- China
- Volunteers
- 11,527 people, healthy volunteers welcome
- Sponsor
- Peking University
COVID - 19, SARS CoV-2
Effect of COV2 Vaccine Formulation on the Ability to Generate Antibodies Against Coronavirus That Causes COVID-19
This is a Phase 1a, single-country, single-centre, single-blinded, COV2 vaccine formulation randomized trial designed to investigate and compare the safety and immunogenicity of two COV2 vaccine formulations.
- Trial name
- NCT07416539
- Testing
- COVID-19 Vaccines
- Where
- Finland
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Rokote Laboratories Finland Oy
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.